Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity

British Journal of Dermatology

Volumn 162, Issue 1, 2010, Pages 29-41

  Mitsui, H ^a   Okamoto, T ^a   Kanzaki, M ^a   Inozume, T ^a   Shibagaki, N ^a   Shimada, S ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Antigen presentation processing; Protein transduction; Skin inflammation; T cells; Vaccine

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYBRID PROTEIN; HYBRID PROTEIN R9 OVA; HYBRID PROTEIN R9 PTD; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; POLYARGININE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SKIN; TH1 CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS; IMMUNOGLOBULIN G; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; OVALBUMIN; RECOMBINANT FUSION PROTEINS; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 72749093583     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09490.x     Document Type: Article

References (32)

1. Chauhan A, Tikoo A, Kapur AK et al. The taming of the cell penetrating domain of the HIV tat: myths and realities. J Control Release 2007 117 : 148 162.
2. Patel LN, Zaro JL, Shen W-C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 2007 24 : 1977 1992.
3. Goun EA, Pillow TH, Jones LR et al. Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem 2006 7 : 1497 1515.
4. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005 57 : 579 596.
5. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005 102 : 247 253.
6. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004 43 : 2438 2444.
7. Cai S-R, Xu G, Becker-Hapak M et al. The kinetics and tissue distribution of protin transduction in mice. Eur J Pharm Sci 2006 27 : 311 319.
8. Kim D, Jeon C, Kim J-H et al. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 2006 312 : 1277 1288.
9. Mitsui H, Inozume T, Kitamura R et al. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 2006 126 : 1804 1812.
10. Inozume T, Mitsui H, Okamoto T et al. Dendritic cells transduced with autoantigen FCRLA induce cytotoxic lymphocytes and vaccinate against murine B-cell lymphoma. J Invest Dermatol 2007 127 : 2818 2822.
11. Ikegawa T, Yamasaki Y, Shakushiro K et al. Induction of cytotoxic T lymphocytes following immunization with cationized soluble antigen. Vaccine 2004 22 : 2609 2616.
12. Yamasaki Y, Ikenaga T, Otsuki T et al. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery. Vaccine 2007 25 : 85 91.
13. Reddy KVR, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents 2004 24 : 536 547.
14. Bhat S, Milner S. Antimicrobial peptides in burns and wounds. Curr Protein Pept Sci 2007 8 : 506 520.
15. Djanani A, Mosheimer B, Kaneider NC et al. Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin. J Inflamm (Lond) 2006 3 : 14.
16. Coyle AJ, Perretti F, Manzini S et al. Cationic protein-induced sensory nerve activation: role of substance P in airway hyperresponsiveness and plasma protein extravasation. J Clin Invest 1994 94 : 2301 2306.
17. Madison JM, Schramm CM. Cationic proteins and bronchial hyperresponsiveness. Am J Respir Cell Mol Biol 2000 22 : 513 516.
18. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004 64 : 5839 5849.
19. Porgador A, Yewdell JW, Deng Y et al. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997 6 : 715 726.
20. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002 168 : 2393 2401.
21. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005 174 : 4880 4891.
22. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007 204 : 49 55.
23. Inozume T, Matsuzaki Y, Kurihara S et al. Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients. Int J Cancer 2005 114 : 283 290.
24. Mendez S, Gurunathan S, Kamhawi S et al. The potency and durability of DNA-, and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001 166 : 5122 5128.
25. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988 54 : 777 785.
26. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 in tumor eradication in vivo. J Exp Med 1999 190 : 617 627.
27. Brockstedt DG, Podsakoff GM, Fong L et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 1999 92 : 67 75.
28. Dobrzanski MJ, Reome JB, Dutton RW. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000 164 : 916 925.
29. Bellone M, Cantarella D, Castiglioni P et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000 165 : 2651 2656.
30. Sato M, Chamoto K, Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int Immunol 2003 15 : 837 843.
31. Chamoto K, Tsujji T, Funamoto H et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004 64 : 386 390.
32. van Broekhoven CL, Parish CR, Demangel C et al. Targeting dendritic cells with antigen-containing liposome: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004 64 : 4357 4365.